KR102201406B1 - Preparation method for bamboo salt with anti-oxidation active material and bamboo salt made therefrom - Google Patents
Preparation method for bamboo salt with anti-oxidation active material and bamboo salt made therefrom Download PDFInfo
- Publication number
- KR102201406B1 KR102201406B1 KR1020190145917A KR20190145917A KR102201406B1 KR 102201406 B1 KR102201406 B1 KR 102201406B1 KR 1020190145917 A KR1020190145917 A KR 1020190145917A KR 20190145917 A KR20190145917 A KR 20190145917A KR 102201406 B1 KR102201406 B1 KR 102201406B1
- Authority
- KR
- South Korea
- Prior art keywords
- antioxidant
- bamboo salt
- bamboo
- drying
- salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 94
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 89
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 89
- 241001330002 Bambuseae Species 0.000 title claims abstract description 89
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 89
- 239000011425 bamboo Substances 0.000 title claims abstract description 89
- 239000011149 active material Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 230000003064 anti-oxidating effect Effects 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 98
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 91
- 238000001035 drying Methods 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 230000000704 physical effect Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000005507 spraying Methods 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims description 27
- 235000008434 ginseng Nutrition 0.000 claims description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 23
- 238000010298 pulverizing process Methods 0.000 claims description 15
- 235000002789 Panax ginseng Nutrition 0.000 claims description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 244000170916 Paeonia officinalis Species 0.000 claims description 3
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 241000208340 Araliaceae Species 0.000 claims 1
- 238000000227 grinding Methods 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 71
- 235000006708 antioxidants Nutrition 0.000 description 68
- 240000004371 Panax ginseng Species 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 241000125175 Angelica Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000736199 Paeonia Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229930182494 ginsenoside Natural products 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical group 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- -1 decursin Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- PHVSWPDOXIQPTN-UHFFFAOYSA-N sedanonic acid Chemical compound CCCCC(=O)C1CCCC=C1C(O)=O PHVSWPDOXIQPTN-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- HXCGUCZXPFBNRD-DNLMCPORSA-N Nodakenin Chemical compound CC(C)([C@@H]1OC2=CC=3OC(=O)C=CC=3C=C2C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HXCGUCZXPFBNRD-DNLMCPORSA-N 0.000 description 1
- HXCGUCZXPFBNRD-QVYYAULWSA-N Nodakenin Natural products O(C(C)(C)[C@@H]1Oc2c(cc3c(OC(=O)C=C3)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HXCGUCZXPFBNRD-QVYYAULWSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- HXCGUCZXPFBNRD-UHFFFAOYSA-N nodakenine Natural products C1C2=CC=3C=CC(=O)OC=3C=C2OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O HXCGUCZXPFBNRD-UHFFFAOYSA-N 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
- A23P20/15—Apparatus or processes for coating with liquid or semi-liquid products
- A23P20/18—Apparatus or processes for coating with liquid or semi-liquid products by spray-coating, fluidised-bed coating or coating by casting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 항산화 활성물질이 포함된 죽염 및 그 제조방법에 관한 것으로, 더욱 상세하게는 식품으로 사용되는 죽염의 제조 공정을 개선하여 항산화물질이 성분 파괴를 최소화하는 항산화 활성물질이 포함된 죽염 및 그 제조방법에 관한 것이다.The present invention relates to a bamboo salt containing an antioxidant active substance and a method for manufacturing the same, and more particularly, to a bamboo salt containing an antioxidant active substance that minimizes the destruction of ingredients of antioxidants by improving the manufacturing process of bamboo salt used as food, and It relates to a manufacturing method.
일반적으로 소금은 인간생활에서 없어서는 안 될 중요한 요소의 하나로, 예로부터 식품조미료뿐만 아니라 미용재료, 공업 용 원료로서 널리 사용되어 왔다.In general, salt is one of the indispensable and important elements in human life, and has been widely used as a beauty material and industrial raw material as well as food seasoning since ancient times.
죽염은 이러한 소금을 대나무와 함께 고온에서 여러 번 가열하고 용융함으로써 몸에 해로운 성분들을 없애고 대나무의 유익한 성분을 추가한 소금을 가리킨다.Bamboo salt refers to the salt obtained by heating and melting these salts together with bamboo at high temperature several times to remove harmful ingredients and add the beneficial ingredients of bamboo.
죽염은 대나무와 소금을 불을 이용하여 합성한 것으로서 이는 세포의 생신작용(生新作用)을 하는 대나무와 살균으로 부패를 방지하는 소금을 소성로에서 고열로 반복 처리하여, 이들이 가지고 있는 약효를 최대한 증진시킨 가공소금의 일종이다. Bamboo salt is synthesized by using bamboo and salt using fire, and it is repetitively treated with high heat in a sintering furnace to prevent decay by sterilization and bamboo, which acts as a living body of cells. It is a kind of processed salt.
이에, 죽염은 다양한 미네랄이 함유되어 생체활성화에 꼭 필요한 소금의 약성을 배가시키고 소금 속에 들어있는 불순물을 제거한 가공 소금으로서 소금이 쓰이는 모든 식품뿐만 아니라 치약, 비누 등 일상생활 전반에 걸쳐 대 단히 광범위하게 사용되고 있다. As a result, bamboo salt is a processed salt that doubles the strength of salt, which is essential for bioactivation as it contains various minerals, and removes impurities in the salt. It is widely used throughout daily life such as toothpaste and soap, as well as all foods that use salt. Is being used.
소금의 단점을 없애고 장점을 강화시키기 위해 우리 조상들은 민간요법으로 소금을 대나무에 구워 사용하였는데 특히 풍치에 효과를 많이 보았으며, 소화가 안 될 때에도 사용하였다. To eliminate the shortcomings of salt and reinforce its strengths, our ancestors used salt baked in bamboo as a folk remedy, which was especially effective in taste and was used even when digestion was not possible.
통상적으로 죽염은 약성을 강화하기 위해서는 황토와 소나무를 이용하여 죽염 제조 시에 대나무의 죽력 성분과 황토와 소나무 불이 만나 발생하는 원적외선 등을 함유한 죽염이 개발되어 사용되고 있다.In general, bamboo salt is developed and used by using ocher and pine to reinforce its medicinal properties, and it contains the bamboo power component of bamboo and far-infrared rays that occur when the fires of red clay and pine trees meet when making bamboo salt.
이런, 죽염의 제조 공정은 죽염 제조 시에 죽염의 자체 약성을 강화하는 것으로, 그 효과가 미비하고, 추가되는 성분도 제한적인 문제점이 있었다.This, the manufacturing process of bamboo salt is to strengthen the self-medicating properties of bamboo salt during the manufacture of bamboo salt, the effect is insufficient, there was a problem that the added ingredients are limited.
이에, 최근에는 건강에 이로운 다양한 성분을 포함하기 위해서는 건강에 이로운 기능성 성분을 혼합한 기능성 죽염이 개발되어 사용되고 있다.Thus, in recent years, in order to include a variety of ingredients beneficial to health, functional bamboo salt mixed with functional ingredients beneficial to health has been developed and used.
그러나, 죽염에 혼합되는 기능성 물질은 분말 형태로 단순 혼합하게 되면 죽염과의 비중과 중량에 차이에 따라 한쪽으로 뭉치거나 균일하게 분포되지 못하여 죽염의 사용 시 기능성 물질이 불균일하게 함유되어 기능의 활성화가 되지 않는 문제점이 있었다.However, if the functional substances mixed in bamboo salt are simply mixed in powder form, they cannot be aggregated or distributed uniformly depending on the difference in specific gravity and weight with bamboo salt. There was a problem that did not work.
또한, 기능성 물질은 천연성분의 경우에 분말로 제조하기 위해서 열풍으로 건조한 후에 분쇄하게 되면 물성이 변하여 특유에 성분이 손상되어 활성화가 어려운 문제점이 있었다.In addition, in the case of natural ingredients, when pulverized after being dried with hot air in order to prepare a powder, the physical properties change, and the characteristic ingredient is damaged, making it difficult to activate.
아울러, 활성산소는 체내의 호기성 대사과정에 의해 생성되어 약 5%는 유리기의 전자를 가지는 원자나 분자의 자유라디칼 형태로 변형되어 인체 내로 침입한 병원균을 사멸시킨다. 그러나, 자유라디칼은 상태가 매우 불안정하고 반응성이 강해 단백질, 지질분자, DNA 등을 포함하는 세포에 산화적 손상을 입히게 되고 이에 따라 암, 빈혈, 심근경색, 뇌성마비, 동맥경화증 등의 이차적인 질병을 발현시킨다.In addition, active oxygen is produced by aerobic metabolic process in the body, and about 5% is transformed into free radical form of atoms or molecules having electrons of free radicals, thereby killing pathogens invading the human body. However, free radicals are very unstable and highly reactive, causing oxidative damage to cells containing proteins, lipid molecules, DNA, etc., resulting in secondary diseases such as cancer, anemia, myocardial infarction, cerebral palsy, and atherosclerosis. Is expressed.
또한, 활성산소에 의한 세포의 산화적 손상과 외부로부터의 자극에 의해 다양한 형태의 염증반응이 발현될 수 있다. 염증반응은 신체 조직의 손상에 대한 생체조직의 국소적인 방어보호반응으로서 대식세포가 분비하는 종양괴사인자-α(TNF-α), 인터루킨-6(IL-6), 인터루킨-1β(IL-1β) 등을 포함하는 사이토카인(Cytokine), 활성산소종, 활성질소종, 염증매개체 등을 포함하는 다양한 물질이 관여한다.In addition, various types of inflammatory reactions may be expressed by oxidative damage to cells by free radicals and stimulation from the outside. Inflammatory response is a local protective and protective reaction of living tissue against damage to body tissues. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) secreted by macrophages. ), including cytokines, reactive oxygen species, active nitrogen species, and inflammatory mediators.
한편, 사이토카인 및 활성질소종에 의해 염증반응이 진행되나 사이토카인 및 활성질소종이 과발현되면 각종 장기 및 신체 기관에 첨착되어 조직손상을 유발하고 유전자변이, 신경손상, 부종, 가려움 등을 더욱 악화시키는 문제가 있었다. 특히, 사이토카인은 면역물질로서, 과발현되는 경우 정상세포를 공격하는 면역 과잉반응을 일으켜 신체 면역력을 약화시키고 조직 내 염증 및 출혈, 40 ℃ 이상의 고열 등을 일으키는 문제가 있었다.On the other hand, the inflammatory reaction proceeds by cytokines and active nitrogen species, but when cytokines and active nitrogen species are overexpressed, they are attached to various organs and body organs, causing tissue damage, and further exacerbating genetic mutation, nerve damage, swelling, and itching. There was a problem. In particular, cytokines are immune substances, and when overexpressed, they cause an immune overreaction that attacks normal cells, weakening the body's immunity, and causing inflammation and bleeding in the tissues, and a high fever of 40°C or higher.
이러한 문제를 해결하기 위해, 세포의 산화적 손상을 방지하는 합성 항산화제 및 천연 항산화제에 대한 연구가 활발히 진행되고 있다.To solve this problem, studies on synthetic antioxidants and natural antioxidants that prevent oxidative damage to cells have been actively conducted.
BHA(Butylated hydroxy anisole), BHT(Butylated hydroxy toluene), NDGA(Nordihydroguaiaretic acid) 등과 같은 합성 항산화제의 경우 알러지 및 종양을 유발하고 열에 약한 문제가 있어 천연 항산화제에 대한 관심이 높아지고 있다. 대한민국 등록특허 제 10-0506384호에서는 당귀, 천궁, 작약 등의 천연물질로부터 얻어지며 산화적 생체 손상을 억제할 수 있는 생약조성물에 대해 개시하고 있으나, 산화적 생체 손상의 억제 효과, 및 면역 효과가 미약하며, 염증반응에 의해 과발현된 사이토카인, 활성질소종에 의한 신체적 손상에는 대비하지 못하는 문제가 있었다.Synthetic antioxidants, such as butylated hydroxy anisole (BHA), butylated hydroxy toluene (BHT), and nordihydroguaiaretic acid (NDGA), cause allergies and tumors, and are weak in heat.Therefore, interest in natural antioxidants is increasing. Korean Patent Registration No. 10-0506384 discloses a herbal composition that is obtained from natural substances such as angelica, cheonggung, and peony and is capable of inhibiting oxidative biological damage, but has an inhibitory effect on oxidative biological damage and an immune effect. It is weak, and there is a problem of not being able to prepare for physical damage due to cytokines and active nitrogen species overexpressed by inflammatory reactions.
이에, 천연의 항산화물질을 손상없이 많이 섭취되는 죽염에 포함시키는 기술의 개발이 요구되고 있는 실정이다.Accordingly, there is a demand for the development of a technology for including natural antioxidants in bamboo salt, which is consumed a lot without damage.
본 발명은 상술한 문제점을 해결하기 위하여 안출된 것으로, 본 발명의 목적은 항산화 작용을 하는 성분을 가지는 재료를 선정하여 물성 변화를 최소화하는 냉동건조로 성분을 유지하면서 죽염에 항산화물질이 결정에 코팅되도록 제조함으로써, 항산화물질을 포함하면서 죽염의 특성을 유지하는 항산화 활성물질이 포함된 죽염 및 그 제조방법을 제공함에 있다. The present invention was conceived to solve the above problems, and an object of the present invention is to select a material having an antioxidant action to minimize the change in physical properties, while maintaining the component, antioxidants are coated on the crystals By manufacturing so as to be, it is intended to provide a bamboo salt containing an antioxidant and a method of manufacturing the same, while including an antioxidant, while maintaining the properties of the bamboo salt.
본 발명의 목적들은 이상에서 언급한 목적들로 제한되지 않으며, 언급되지 않은 또 다른 목적들은 아래의 기재로부터 명확하게 이해될 수 있을 것이다.The objects of the present invention are not limited to the above-mentioned objects, and other objects that are not mentioned will be clearly understood from the following description.
상기 목적을 달성하기 위하여, 본 발명이 일 실시예에 따른 항산화 활성물질이 포함된 죽염 제조방법은 소금을 대나무와 함께 가열하여 제조된 죽염을 기설정된 크기로 분쇄함으로써, 죽염을 제조하여 분쇄하는 단계; 상기 죽염에 함유되는 항산화물질을 물성과 원형을 유지하도록 냉동한 상태에서 건조하는 항산화물질을 냉동한 상태로 건조하는 단계; 상기 항산화물질 건조단계에서 건조된 상기 항산화물질을 기설정된 크기로 분쇄하는 항산화물질을 분쇄하는 단계; 분쇄된 상기 항산화물질에 물을 공급하여 용해도가 낮은 상태의 겔화시키는 항산화물질을 겔상태로 처리하는 단계; 상기 항산화물질 겔을 상기 죽염에 분사하여 상기 죽염의 흡수력에 의해 코팅을 실시하는 항산화물질을 죽염에 코팅하는 단계; 및 상기 항산화물질을 코팅한 죽염을 건조하여 항산화 활성물질이 포함된 죽염의 제조를 종료하는 단계;를 포함한다.In order to achieve the above object, the method for producing bamboo salt containing an antioxidant active material according to an embodiment of the present invention comprises pulverizing the bamboo salt prepared by heating the salt with bamboo to a predetermined size, thereby producing and pulverizing bamboo salt. ; Drying the antioxidants contained in the bamboo salt in a frozen state to maintain physical properties and originality; Pulverizing the antioxidant by grinding the antioxidant dried in the antioxidant drying step to a predetermined size; Supplying water to the pulverized antioxidant material to treat an antioxidant that is gelled in a low solubility state into a gel state; Spraying the antioxidant gel onto the bamboo salt to coat the bamboo salt with an antioxidant that is coated by the absorption power of the bamboo salt; And drying the bamboo salt coated with the antioxidant to terminate the production of the bamboo salt containing the antioxidant active material.
또한, 상기 항산화물질은 인삼, 홍삼, 당귀, 천궁, 및 작약 중에 하나 또는 둘이상의 혼합물일 수 있다.In addition, the antioxidant may be a mixture of one or two or more of ginseng, red ginseng, angelica, cheonggung, and peony.
그리고, 상기 항산화물질을 냉각한 상태로 건조하는 단계는, 상기 항산화물질을 냉동건조기에 투입한 상태에서 기설정된 냉동온도로 냉각하고, 기설정된 온도에 도달하면 진공 상태를 만들도록 내부 공기와 함께 습기를 흡입하여 건조를 실시하고, 흡입 후에 기설정된 냉동온도를 유지한 후에 기설정된 기간이 지나면 온도를 상승시켜 건조를 마칠 수 있다.And, in the step of drying the antioxidant in a cooled state, the antioxidant is cooled to a preset freezing temperature in a state in which the antioxidant is put in a freeze dryer, and when the temperature reaches a preset temperature, moisture with internal air is created to create a vacuum state. Drying may be performed by inhaling and, after inhalation, a preset freezing temperature is maintained, and after a preset period has elapsed, the temperature is increased to complete drying.
아울러, 본 발명의 일실시예에 따른 항산화 활성물질이 포함된 죽염은 항산화물질을 냉동 건조한 분말에 물을 투입하여 겔 상태로 기설정된 크기로 분쇄된 죽염에 분사하여 각 결정의 겉면에 코팅한다.In addition, the bamboo salt containing an antioxidant active substance according to an embodiment of the present invention is coated on the outer surface of each crystal by spraying the crushed bamboo salt into a predetermined size in a gel state by adding water to the freeze-dried powder.
더불어, 상기 항산화물질은 인삼, 홍삼, 당귀, 천궁, 및 작약 중에 하나 또는 둘이상의 혼합물일 수 있다.In addition, the antioxidant may be a mixture of one or two or more of ginseng, red ginseng, angelica, cheonggung, and peony.
상기 목적을 달성하기 위한 구체적인 사항들은 첨부된 도면과 함께 상세하게 후술된 실시예들을 참조하면 명확해질 것이다.Detailed matters for achieving the above object will become apparent with reference to the embodiments described later in detail together with the accompanying drawings.
그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라, 서로 다른 다양한 형태로 구성될 수 있으며, 본 실시예들은 본 발명의 개시가 완전하도록 하고 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이다.However, the present invention is not limited to the embodiments disclosed below, but may be configured in a variety of different forms, and these embodiments are intended to complete the disclosure of the present invention and provide common knowledge in the technical field to which the present invention pertains. It is provided to fully inform the possessor of the scope of the invention.
전술한 본 발명의 과제 해결 수단 중 하나에 의하면, 항산화 작용을 하는 성분을 가지는 재료를 선정하여 물성 변화를 최소화하는 냉동건조로 성분을 유지하면서 죽염에 항산화물질이 결정에 코팅되도록 제조함으로써, 항산화물질을 포함하면서 죽염의 특성을 유지하는 효과를 제공한다.According to one of the above-described problem solving means of the present invention, by selecting a material having an antioxidant function and maintaining the component by freeze drying to minimize the change in physical properties, it is prepared so that the antioxidant is coated on the crystal. It provides the effect of maintaining the characteristics of bamboo salt while including.
도 1은 본 발명의 일 실시예에 따른 항산화 활성물질이 포함된 죽염의 제조방법을 나타내는 공정도이다.
도 2는 본 발명의 일 실시예에 따른 항산화 활성물질이 포함된 죽염을 나타내는 단면도이다.1 is a flow chart showing a method of manufacturing bamboo salt containing an antioxidant active substance according to an embodiment of the present invention.
2 is a cross-sectional view showing bamboo salt containing an antioxidant active material according to an embodiment of the present invention.
본 발명은 다양한 변경을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 이를 상세한 설명을 통해 상세히 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다.In the present invention, various modifications may be made and various embodiments may be provided. Specific embodiments are illustrated in the drawings and will be described in detail through detailed description. However, this is not intended to limit the present invention to a specific embodiment, it is to be understood to include all changes, equivalents, and substitutes included in the spirit and scope of the present invention.
본 발명을 설명함에 있어서, 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우, 그 상세한 설명을 생략한다. 또한, 본 명세서의 설명 과정에서 이용되는 숫자(예를 들어, 제1, 제2 등)는 하나의 구성요소를 다른 구성요소와 구분하기 위한 식별기호에 불과하다.In describing the present invention, when it is determined that a detailed description of a related known technology may unnecessarily obscure the subject matter of the present invention, a detailed description thereof will be omitted. In addition, numbers (eg, first, second, etc.) used in the description of the present specification are merely identification symbols for distinguishing one component from another component.
또한, 본 명세서에서, 일 구성요소가 다른 구성요소와 "연결된다" 거나 "접속된다" 등으로 언급된 때에는, 상기 일 구성요소가 상기 다른 구성요소와 직접 연결되거나 또는 직접 접속될 수도 있지만, 특별히 반대되는 기재가 존재하지 않는 이상, 중간에 또 다른 구성요소를 매개하여 연결되거나 또는 접속될 수도 있다고 이해되어야 할 것이다.In addition, in the present specification, when one component is referred to as "connected" or "connected" to another component, the one component may be directly connected or directly connected to the other component, but specially It should be understood that as long as there is no opposing substrate, it may be connected or may be connected via another component in the middle.
이하의 설명에서 사용되는 구성요소에 대한 접미사 "모듈" 및 "부"는 명세서 작성의 용이함만이 고려되어 부여되거나 혼용되는 것으로서, 그 자체로 서로 구별되는 의미 또는 역할을 갖는 것은 아니다. 또한, 본 발명을 명확하게 설명하기 위하여 설명과 관계없는 부분은 도면에서 생략하였으며, 도면들에 있어서 구성요소의 폭, 길이, 두께 등은 편의를 위하여 과장되어 표현될 수 있다. 명세서 전체에 걸쳐서 동일한 참조부호들은 동일한 구성요소들을 나타낸다.The suffixes "module" and "unit" for components used in the following description are given or used interchangeably in consideration of only the ease of preparation of the specification, and do not have meanings or roles that are distinguished from each other by themselves. In addition, in order to clearly describe the present invention, parts irrelevant to the description are omitted from the drawings, and in the drawings, the width, length, thickness, etc. of the components may be exaggerated for convenience. Like reference numerals indicate like elements throughout the specification.
이하, 첨부된 도면들을 참조하여 본 발명의 실시를 위한 구체적인 내용을 설명하도록 한다.Hereinafter, with reference to the accompanying drawings will be described in detail for the implementation of the present invention.
도 1은 본 발명의 일 실시예에 따른 항산화 활성물질이 포함된 죽염의 제조방법을 나타내는 공정도이다.1 is a flow chart showing a method of manufacturing bamboo salt containing an antioxidant active material according to an embodiment of the present invention.
도 1를 참고하면 본 발명의 항산화 활성물질이 포함된 죽염 제조방법은 항산화물질의 물성과 성분에 변화를 최소화하면서 분말화하는 동결 건조 과정을 거쳐서 용해도가 낮은 겔형태로 제조하여 죽염(10)의 결정의 겉면으로 코팅되어 항산화 활성물질을 포함한 죽염을 제조하는 방법이다.Referring to FIG. 1, the method of manufacturing bamboo salt containing an antioxidant active substance of the present invention is prepared in a gel form with low solubility through a freeze-drying process of powdering while minimizing changes in properties and components of the antioxidant. It is a method of manufacturing bamboo salt containing an antioxidant active substance by coating the surface of the crystal.
이런, 항산화 활성물질이 포함된 죽염 제조방법은 죽염제조분쇄단계(S10), 냉동건조단계(S20), 항산화분쇄단계(S30), 겔화단계(S40), 코팅단계(S50), 및 제조종료단계(S60)를 포함한다. Such, the manufacturing method of bamboo salt containing an antioxidant active material is the bamboo salt manufacturing pulverization step (S10), freeze drying step (S20), antioxidant pulverization step (S30), gelation step (S40), coating step (S50), and manufacturing termination step. (S60) is included.
죽염제조분쇄단계(S10)는 소금을 대나무와 함께 가열하여 제조된 죽염(10)을 기설정된 크기로 분쇄함으로써, 죽염을 제조하여 분쇄를 실시하는 단계이다.The bamboo salt manufacturing pulverization step (S10) is a step of pulverizing the
즉, 죽염제조분쇄단계(S10)는 미네랄이 포함되어 있는 천일염을 원료로 하여 대나무 내부에 담은 상태에서 황토 내에서 가열을 실시하여 원적외선이 포함되는 죽염을 제조하고, 제조된 서로 크기가 다른 죽염(10)을 기설정된 크기가 되도록 분쇄함으로써, 죽염을 제조하여 분쇄를 실시하는 단계이다.That is, the bamboo salt manufacturing and pulverization step (S10) is a raw material containing natural sea salt containing minerals and heated in the loess in the state of being contained inside the bamboo to produce bamboo salt containing far-infrared rays. 10) is a step of pulverizing to prepare bamboo salt by pulverizing to a predetermined size.
냉동건조단계(S20)는 죽염(10)에 함유되는 항산화물질(20)을 물성과 원형을 유지하도록 냉동한 상태에서 건조하는 항산화물질(20)을 냉동한 상태로 건조하는 단계이다.The freeze-drying step (S20) is a step of drying the
이때, 항산화물질(20)은 인삼, 홍삼, 당귀, 천궁, 및 작약 중에 하나 또는 둘이상의 혼합물이다.At this time, the
여기서, 인삼은 주로 한국, 중국, 일본 등의 아시아 국가에서 생약의 형태로 정신 의학적 질병, 신경계의 질병 및 당뇨병 등 여러 가지 질병에 대해 사용되어 왔으며, 상기 인삼의 주요 성분인 사포닌은 강장, 강정, 진정, 조혈 및 항고혈압 등에 효과를 보이는 것으로 알려져 있다(和漢藥百科圖鑑, 1권 1-8쪽, 남바쯔네히끼, 호이꾸사, 1980년). 인삼은 재배하여 채취한 상태 그대로의 수삼을 상온에서 건조시킨 백삼 또는 수삼을 98~100℃에서 가열 처리하여 제조되는 홍삼, 또는 120~180℃에서 가열 처리하여 제조되는 선삼의 형태로 사용되고 있다. 인삼중의 주성분인 진세노시드 Rb1, Rb2, Rc 등의 인삼 사포닌을 들 수 있는데 사포닌은 주로 담마란(dammarane)계 비배당체와 각각 다른 수의 몇가지 당류로 구성된 트리테르펜 글리코시드(triterpene glycosides)로서 근부 및 지상부에서 40여 종류가 밝혀져 있다. 진세노사이드의 경우 뿌리보다 잎에 훨씬 더 많이 존재하며, 인삼잎에는 뿌리에는 없는 인삼잎 특이적인 진세노사이드가 존재한다고 알려져 있다(Yahara et al., Chem. Pharm. Bull., 1979, 27, 88). 또한, 진세노시드 Rb1, Rb2 및 Rc는 사람의 장내 세균총에 의하여 진세노시드 Rd를 경유하여 주로 화합물 K로 대사된다. 이 대사과정을 촉매하는 균주로 알려진 것은 프로보텔라 오리스(Provotella oris) 및 푸소박테리움 K-60 균주이다. 한편 이러한 인삼 사포닌을 약산으로 처리하면 진세노시드 Rg3로 전환되며 이 화합물은 푸소박테리움 K-60 균주 등의 장내 세균에 의하여 진세노시드 Rh2로 전환된다. 이 경우에 생성된 화합물 K(20-Ο-β-Dglucopyranosyl-20(S)-protopanaxadiol) 및 진세노시드 Rh2는 암세포에 대한 세포독성이나 암세포의 암전이를 억제하는 것으로 알려져 있다(Mochizuki, M. et al., Biol. Pharm. Bull., 18: 1197-1202, 1995; Wakabayashi, C.H., et al., Oncol. Res., 9: 411-417, 1998).Here, ginseng has been mainly used in the form of herbal medicines in Asian countries such as Korea, China, and Japan for various diseases such as psychiatric diseases, diseases of the nervous system, and diabetes, and saponins, which are major components of ginseng, are tonic, gangjeong, It is known to have an effect on sedation, hematopoiesis, and antihypertension (和漢藥百科圖鑑, Vol. 1, p. 1-8, Nambatsunehiki, Hoikusa, 1980). Ginseng is used in the form of white ginseng produced by drying fresh ginseng as it is grown and collected at room temperature, or red ginseng produced by heat-treated fresh ginseng at 98~100℃, or sun ginseng produced by heat treatment at 120~180℃. Ginseng saponins such as ginsenosides Rb1, Rb2, and Rc, which are the main components of ginseng, are mentioned. Saponins are triterpene glycosides composed mainly of dammarane non-glycosides and a number of different sugars. More than 40 species have been identified in the root and above ground. Ginsenosides are much more present in leaves than in roots, and ginseng leaves are known to have ginseng leaf-specific ginsenosides that are not present in the roots (Yahara et al., Chem. Pharm. Bull., 1979, 27, 88). In addition, ginsenosides Rb1, Rb2 and Rc are mainly metabolized to compound K through ginsenoside Rd by the human gut flora. Known strains that catalyze this metabolic process are Provotella oris and Fusobacterium K-60 strains. On the other hand, when this ginseng saponin is treated with a weak acid, it is converted to ginsenoside Rg3, and this compound is converted to ginsenoside Rh2 by intestinal bacteria such as Fusobacterium K-60 strain. In this case, the produced compound K (20-Ο-β-Dglucopyranosyl-20(S)-protopanaxadiol) and ginsenoside Rh2 are known to inhibit cytotoxicity to cancer cells or cancer metastasis of cancer cells (Mochizuki, M. et al., Biol. Pharm. Bull., 18: 1197-1202, 1995; Wakabayashi, CH, et al., Oncol. Res., 9: 411-417, 1998).
홍삼은 수삼을 가열 처리하여 제조되는 것으로서 백삼에 비하여 우수한 약효를 가지고 있는 것으로 널리 알려져 있다. 특히, 홍삼에는 수삼, 백삼에 함유되지 않은 진세노사이드 Rg3, Rg5, Rk1, Rh2, Rh1, 말톨 등 미량 성분이 존재하여 약효가 증가하는 것으로 알려졌다. 가정에서 수삼 이나 백삼에서 홍삼 엑기스를 제조할 수 있는 방법이 고안되어 그 제조를 위한 기계도 이미 알려진 바 있다(대한민국 특허 공개번호 제 10-2001-19628호). 이처럼 홍삼에 미량 함유된 성분을 강화하여 약효를 증강시키는 방법들이 연구 되어지고 있다. 고려인삼은 중초약학(中草藥學)에서 원기를 크게 보하고 폐를 튼튼하게 하며 비장(脾臟)을 좋게 하고 심장을 편안하게 해준다고 했으며, 신농본초경(神農本草徑)에는 인삼은 오장(五臟) 즉 간장, 심장, 폐장, 신장, 비장의 양기(陽氣)를 돋구어 주는 주약으로 사용하고 정신을 안정시키고 오부로 진입하는 병사(病邪)를 제거하여 주며 눈을 밝게 하고 지혜롭게 하고 오래 복용하면 몸이 가벼워지고 장수한다고 하였다.Red ginseng is produced by heat treatment of fresh ginseng, and is widely known to have superior medicinal effects compared to white ginseng. In particular, it is known that red ginseng contains trace components such as ginsenosides Rg3, Rg5, Rk1, Rh2, Rh1, and maltol, which are not contained in fresh ginseng and white ginseng, which increases the medicinal effect. A method for manufacturing red ginseng extract from fresh or white ginseng at home has been devised, and a machine for manufacturing the same has already been known (Korean Patent Publication No. 10-2001-19628). In this way, methods to enhance the medicinal effect by strengthening the ingredients contained in red ginseng are being studied. Korean ginseng is said to provide greater vitality, strengthen the lungs, improve the spleen, and relax the heart in Jungcho Pharmacy. In Shinnongbonchogyeong, ginseng is a five-jang or soy sauce. , It is used as a main medicine that boosts the yang of the heart, lungs, kidneys, and spleen. It stabilizes the mind and removes the soldiers who enter the obituary. It brightens the eyes and makes the body lighter if taken for a long time. It was said to lose and live long.
당귀는 산형과에 속하는 참당귀의 뿌리를 건조시킨 것으로 데커신, 데쿠르트시놀, 노다케네린, 움벨리프레닌, 노다케닌, 크산도톡신, 이소핌피넬린, 오스톨 등 다양한 형태의 쿠마린(Coumarin) 성분을 다량 함유되어 있어 우수한 항산화 작용을 하며 혈액순환 개선, 진통효과, 보혈작용, 항염증 등의 작용을 함에 따라 각종 질병의 예방 및 치료에 사용된다. 특히, 당귀에 함유된 데커신은 쿠마린 유도체로 활성산소를 제거하여 우수한 항산화 작용을 함으로써 세포를 보호하여 신체 기능을 활발히 한다.Angelica is a dried root of Angelica Angelica belonging to the umbel family, and various forms of coumarins such as decursin, decurtsinol, nodakenerin, umbelifrenin, nodakenin, xandotoxin, isopimpineline, and ostol ( As it contains a large amount of (coumarin), it has excellent antioxidant activity, and it is used for the prevention and treatment of various diseases as it improves blood circulation, has analgesic effect, blood restoration, and anti-inflammatory effects. In particular, decursine contained in Angelicae is a coumarin derivative that removes free radicals and acts as an excellent antioxidant to protect cells and activate body functions.
천궁은 쌍떡잎식물 이판화군 산형화목 미나리과의 여러해살이풀로 Tetramethylpyrazine, Perolyrine 등을 포함하는 알킬로이드, Chrysophanoll, Sedanonic acid 등을 포함하는 페놀성 성분, 락톤류, 비타민E 등의 성분이 다량 함유되어 있어 우수한 항산화 작용을 하며 진통효과, 강장효과, 항균작용, 항염증, 면역 강화 등의 작용을 함에 따라 각종 질병의 예방 및 치료에 사용된다.Chungoong is a perennial plant of the parsley family, umbela group of dicotyledons, and is excellent because it contains a large amount of phenolic components including alkyloids including Tetramethylpyrazine, Perolyrine, Chrysophanoll, Sedanonic acid, lactones, and vitamin E. It is used for the prevention and treatment of various diseases as it acts as an antioxidant and has analgesic effect, tonic effect, antibacterial effect, anti-inflammatory, and immunity strengthening.
작약은 미나리아재비과의 여러해살이풀인 함박꽃의 뿌리로 주로 약재로 사용되며 향기가 강하고 꽃이 아름다워 관상용으로도 재배된다. 작약에는 Paeoniflorin, Paeonel, Paeonin, Tannin, β-sitosterol, triterpenoid, 정유, 지방유, 수지 등의 성분이 다량 함유되어 있어 항산화, 항염증, 진통효과, 혈액보강, 면역 강화 등의 작용을 함에 따라 각종 질병의 예방 및 치료에 사용된다. Peony is the root of the perennial plant of the Ranunculus family. It is mainly used as a medicinal material. It is also cultivated for ornamental purposes due to its strong scent and beautiful flowers. Peony contains a large amount of ingredients such as Paeoniflorin, Paeonel, Paeonin, Tannin, β-sitosterol, triterpenoid, essential oils, fatty oils, resins, etc. Various diseases as it acts as an antioxidant, anti-inflammatory, pain reliever, blood reinforcement, and immunity. It is used for the prevention and treatment of.
상술된 항산화물질(20)은 NO 생성을 저해하고, 종양괴사인자-α(TNF-α), 인터루킨-6(IL-6), 인터루킨-1β(IL-1β) 등을 포함하는 사이토카인, 활성산소, 활성질소 등의 과발현을 방지하고 적정량 유지시킴으로써 세포의 산화적 손상, 면역 과잉반응, 면역 저하, 염증 반응 등을 방지하는 항산화, 항염증 또는 면역 강화 활성을 가질 수 있다.The above-described antioxidant (20) inhibits NO production and activates cytokines, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), etc. By preventing overexpression of oxygen, active nitrogen, etc. and maintaining an appropriate amount, it may have antioxidant, anti-inflammatory or immune enhancing activity that prevents oxidative damage, immune hyperreaction, immunity reduction, and inflammatory reaction of cells.
이에 따라, 항산화물질(20)은 항산화, 항염증, 및 면역 강화 작용을 하는 다양한 성분들이 함유됨에 따라 항산화, 항염증, 및 면역 활성 효과를 가질 수 있다.Accordingly, the
상술된 냉동건조단계(S20)는 항산화물질(20)을 냉동건조기에 투입한 상태에서 기설정된 냉동온도로 냉각하고, 기설정된 온도에 도달하면 진공 상태를 만들도록 내부 공기와 함께 습기를 흡입하여 건조를 실시하고, 흡입 후에 기설정된 냉동온도를 유지한 후에 기설정된 기간이 지나면 온도를 상승시켜 건조를 마치는 단계이다.In the freeze-drying step (S20) described above, the
바람직하기로, 항산화물질(20)을 냉동건조기로 투입한 상태에 영하 40도로 냉각하여 재료프리징을 실시한 후에 영하 55~60도를 유지하면서 공기를 빨아들여 진공화하면서 재료에서 나오는 습도를 빼면서 건조를 실시하고, 건조 후에 24시간동안 온도를 단계적으로 상승시켜 건조를 마침에 따라 원형을 보존하면서 활성과 성분 변화를 최소화하면서 건조를 실시한다.Preferably, the
항산화분쇄단계(S30)는 냉동건조단계(S30)에서 건조된 항산화물질(20)을 기설정된 크기로 분쇄하는 항산화물질(20)을 분쇄하는 단계이다.The antioxidant pulverization step (S30) is a step of pulverizing the
즉, 냉동건조된 항산화물질(20)을 겔화 후에 코팅되는 입자의 크기를 고려하여 분쇄를 실시한다.That is, the
겔화단계(S40)는 분쇄된 항산화물질(20)에 물을 공급하여 용해도가 낮은 상태의 겔화시키는 항산화물질(20)을 겔상태로 처리하는 단계이다.In the gelation step (S40), water is supplied to the pulverized
코팅단계(S50)는 항산화물질(20) 겔을 죽염(10)에 분사하여 상기 죽염의 흡수력에 의해 코팅을 실시하는 항산화물질(20)을 죽염(10)에 코팅하는 단계이다. The coating step (S50) is a step of spraying the
즉, 코팅단계(S50)는 분쇄된 죽염을 펼쳐진 상태에서 항산화물질(20) 겔을 균일하게 분사하면 표면에서 일부 흡수되면서 각각의 죽염 바깥 면에 개별적으로 코팅이 실시된다. That is, in the coating step (S50), if the crushed bamboo salt is spread evenly and the
제조종료단계(S60)는 항산화물질(20)을 코팅한 죽염(10)을 건조하여 항산화 활성물질이 포함된 죽염(10)의 제조를 종료하는 단계이다. The manufacturing termination step (S60) is a step of drying the
즉, 제조종료단계(S60)는 죽염(10) 결정에 항산화물질(20) 겔이 표면에 흡수한 상태에서 건조에 의해 고형화하여 항산화물질(20)과 죽염(10)이 일체화되어 항산화 효능이 향상되는 죽염(10)을 제조할 수 있다. In other words, in the manufacturing termination step (S60), the antioxidant (20) gel is absorbed on the surface of the bamboo salt (10) crystal and solidified by drying, so that the antioxidant (20) and bamboo salt (10) are integrated to improve the antioxidant efficacy. It is possible to manufacture bamboo salt (10).
도 2는 본 발명의 일 실시예에 따른 항산화 활성물질이 포함된 죽염을 나타내는 단면도이다.2 is a cross-sectional view showing bamboo salt containing an antioxidant active material according to an embodiment of the present invention.
도 2를 참고하면, 본 발명의 일 실시예에 따른 항산화 활성물질이 포함된 죽염(10)은 항산화물질(20)을 냉동 건조한 분말에 물을 투입하여 겔 상태로 기설정된 크기로 분쇄된 죽염(10)에 분사하여 각 결정의 겉면에 코팅하도록 구비된다.Referring to Figure 2, the
이런, 항산화물질(20)은 인삼, 홍삼, 당귀, 천궁, 및 작약 중에 하나 또는 둘이상의 혼합물로 구비된다. Such, the
이상의 설명은 본 발명의 기술 사상을 예시적으로 설명한 것에 불과한 것으로서, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자라면 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 다양한 수정 및 변형이 가능할 것이다.The above description is merely illustrative of the technical idea of the present invention, and those of ordinary skill in the art to which the present invention pertains will be able to make various modifications and variations without departing from the essential characteristics of the present invention.
따라서, 본 발명에 개시된 실시 예들은 본 발명의 기술 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시 예에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아니다.Accordingly, the embodiments disclosed in the present invention are not intended to limit the technical idea of the present invention, but to explain the technical idea, and the scope of the technical idea of the present invention is not limited by these embodiments.
본 발명의 보호 범위는 아래의 청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.The scope of protection of the present invention should be interpreted by the following claims, and all technical ideas within the scope equivalent thereto should be interpreted as being included in the scope of the present invention.
<도면의 주요부분에 대한 부호의 설명>
10 : 죽염 20 : 항산화물질<Explanation of symbols for major parts of drawings>
10: bamboo salt 20: antioxidant
Claims (5)
상기 죽염에 함유되는 항산화물질을 물성과 원형을 유지하도록 냉동한 상태에서 건조하는 항산화물질을 냉동한 상태로 건조하는 단계;
상기 항산화물질 건조단계에서 건조된 상기 항산화물질을 기설정된 크기로 분쇄하는 항산화물질을 분쇄하는 단계;
분쇄된 상기 항산화물질에 물을 공급하여 용해도가 낮은 상태의 겔화시키는 항산화물질을 겔상태로 처리하는 단계;
분쇄된 상기 죽염을 펼쳐진 상태에서 상기 항산화물질 겔을 균일하게 분사하면 상기 죽염의 표면에서 흡수되면서 각 결정의 바깥면에 개별적으로 코팅을 실시하는 항산화물질을 상기 죽염에 코팅하는 단계; 및
용해도가 낮은 상기 항산화물질 겔을 상기 죽염에 분사하여 코팅한 상태에서 건조에 의해 각 결정별로 고형화하여 상기 항산화물질과 상기 죽염을 일체화한 항산화 활성물질이 포함된 죽염의 제조를 종료하는 단계;를 포함하되,
상기 항산화물질을 냉동한 상태로 건조하는 단계는,
상기 항산화물질을 냉동건조기에 투입한 상태에서 기설정된 냉동온도로 냉각하고, 기설정된 온도에 도달하면 진공 상태를 만들도록 내부 공기와 함께 습기를 흡입하여 건조를 실시하고, 흡입 후에 기설정된 냉동온도를 유지한 후에 기설정된 기간이 지나면 온도를 상승시켜 건조를 마치고,
상기 항산화물질은 인삼, 홍삼, 당귀, 천궁, 및 작약 중에 하나 또는 둘이상의 혼합물인
항산화 활성물질이 포함된 죽염 제조방법.
Pulverizing the prepared bamboo salt by heating the salt with bamboo to a predetermined size;
Drying the antioxidants contained in the bamboo salt in a frozen state to maintain physical properties and originality;
Pulverizing the antioxidant by pulverizing the antioxidant material dried in the antioxidant drying step to a predetermined size;
Supplying water to the pulverized antioxidant to gel the antioxidant in a low solubility state into a gel state;
Coating the bamboo salt with an antioxidant that is applied to the outer surface of each crystal individually while being absorbed from the surface of the bamboo salt when uniformly spraying the antioxidant gel in the unfolded state of the pulverized bamboo salt; And
In a state in which the antioxidant gel with low solubility is sprayed onto the bamboo salt and then solidified for each crystal by drying, terminating the production of bamboo salt containing an antioxidant active material in which the antioxidant and the bamboo salt are integrated. But,
Drying the antioxidant in a frozen state,
In the state of putting the antioxidant in the freeze dryer, cool it to a preset freezing temperature, and when it reaches the preset temperature, dry it by sucking moisture with the internal air to create a vacuum state, and then setting a preset freezing temperature after suction. After maintaining, after a predetermined period of time, the temperature is raised to finish drying,
The antioxidant is a mixture of one or two or more of ginseng, red ginseng, angelica, cheonggung, and peony
Bamboo salt manufacturing method containing antioxidant active substances.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190145917A KR102201406B1 (en) | 2019-11-14 | 2019-11-14 | Preparation method for bamboo salt with anti-oxidation active material and bamboo salt made therefrom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190145917A KR102201406B1 (en) | 2019-11-14 | 2019-11-14 | Preparation method for bamboo salt with anti-oxidation active material and bamboo salt made therefrom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102201406B1 true KR102201406B1 (en) | 2021-01-08 |
Family
ID=74127581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190145917A KR102201406B1 (en) | 2019-11-14 | 2019-11-14 | Preparation method for bamboo salt with anti-oxidation active material and bamboo salt made therefrom |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102201406B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230001635A (en) | 2021-06-29 | 2023-01-05 | 경성대학교 산학협력단 | Method for manufacturing Parenteral formulation using bamboo salt |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110051883A (en) * | 2009-11-11 | 2011-05-18 | 고창군 | Bamboo salt containing rubus coreanus |
| KR20120000382A (en) * | 2010-06-25 | 2012-01-02 | 주식회사 에코덤 | Salt using bambusae calulis in liquamen and functional food composition |
| KR101145169B1 (en) * | 2009-09-30 | 2012-05-16 | 송춘종 | Functional food containing honey and bamboo salt and a manufacturing method thereof |
| KR101612813B1 (en) * | 2014-03-04 | 2016-04-15 | 최인귀 | Manufacturing method of fermented salt containing ginseng steaed red juice |
-
2019
- 2019-11-14 KR KR1020190145917A patent/KR102201406B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101145169B1 (en) * | 2009-09-30 | 2012-05-16 | 송춘종 | Functional food containing honey and bamboo salt and a manufacturing method thereof |
| KR20110051883A (en) * | 2009-11-11 | 2011-05-18 | 고창군 | Bamboo salt containing rubus coreanus |
| KR20120000382A (en) * | 2010-06-25 | 2012-01-02 | 주식회사 에코덤 | Salt using bambusae calulis in liquamen and functional food composition |
| KR101612813B1 (en) * | 2014-03-04 | 2016-04-15 | 최인귀 | Manufacturing method of fermented salt containing ginseng steaed red juice |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230001635A (en) | 2021-06-29 | 2023-01-05 | 경성대학교 산학협력단 | Method for manufacturing Parenteral formulation using bamboo salt |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102551014A (en) | Seasoning | |
| KR102323018B1 (en) | Raw Rice Wine Powder Composition using Germinated Brown Rice and Manufacturing method of thereof | |
| CN105231450B (en) | A kind of pumpkin lozenge and preparation method thereof | |
| KR102201406B1 (en) | Preparation method for bamboo salt with anti-oxidation active material and bamboo salt made therefrom | |
| CN108094872A (en) | A kind of preparation method of improving eyesight nourishing the stomach rice cake | |
| CN106994180A (en) | A kind of traditional Chinese medical science medicine composition with foot health-care function | |
| CN103893063B (en) | A kind of Chinese medicine shampoo that alleviates alopecia after chemotherapy and preparation method thereof | |
| KR102201408B1 (en) | Preparation method for salt with anti-oxidation active material and salt made therefrom | |
| CN105192199A (en) | Preparation process of mulberry leaf tea | |
| CN102028639A (en) | Bitter gourd drug toothpaste | |
| CN104490702A (en) | Herbal mask taking plant extract as anticorrosive antibacterial additive | |
| KR101969983B1 (en) | Shampoo composition for improving hair loss containing soil-board salt and method the same | |
| CN113797275A (en) | Traditional Chinese medicine composition for treating acute mastitis and preparation method thereof | |
| CN112656916A (en) | Traditional Chinese medicine gel with whitening and freckle removing effects and preparation method thereof | |
| CN105168091A (en) | Telangiectasis removing mask powder and preparation method thereof | |
| CN105167097A (en) | Black glutinous rice fermented beverage | |
| CN104489845A (en) | Ginger granules containing mulberry twig extracts and preparation method of ginger granules | |
| KR102400309B1 (en) | Preparation method for Strawberry jam with antioxidant activity and Strawberry jam made therefrom | |
| KR102558720B1 (en) | Functional salt containing oyster extracts and capsosiphon fulvescens | |
| CN105104819A (en) | Medicinal herb preparation for improving meat quality and flavor of Weishan lake northern snakeheads | |
| CN108042610B (en) | Safe dental implant restoration liquid and preparation method thereof | |
| CN107375176B (en) | Whitening, acne removing and skin moistening cosmetic and preparation method thereof | |
| CN105194216A (en) | Barbiers eliminating essence and preparation method of barbiers eliminating essence | |
| CN103976061A (en) | Skin benefiting tea and making method thereof | |
| CN106039159A (en) | Traditional Chinese medicine wine for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant |